Safety, tolerability, and pharmacokinetics of crenezumab in patients with mild-to-moderate Alzheimer’s disease treated with escalating doses for up to 133 weeks

Manuscript Number: 

20-0134R1

Author(s): 
Tobias Bittner, Kathleen Blondeau, Montserrat Carrasco-Triguero, David Clayton, Michael Dolton, Heather Guthrie, Lawrence S. Honig, Qinshu Lian, Helen Lin, Susanne Ostrowitzki, Angelica Quartino, Kaycee M. Sink, Jillian Smith

Disclosures

Tobias Bittner

  • Sponsors:
    Full-time employee of F. Hoffmann-La Roche Ltd.

Kathleen Blondeau

  • Sponsors:
    Full-time employee of F. Hoffmann-La Roche Ltd.

Montserrat Carrasco-Triguero

  • Sponsors:
    Full-time employee of Genentech, Inc.

David Clayton

  • Sponsors:
    Full-time employee of Genentech, Inc.

Michael Dolton

  • Sponsors:
    Full-time employee of Genentech, Inc.

Heather Guthrie

  • Sponsors:
    Full-time employee of Genentech, Inc.

Lawrence S. Honig

  • Consulting Fees:
    Consultant for Eisai and Miller Communications and study investigator for AbbVie, Biogen, Bristol-Myers Squibb, Eisai, Eli Lilly, Genentech, Inc., Lundbeck, F. Hoffmann-La Roche Ltd, and vTv Therapeutics, Inc.

Qinshu Lian

  • Sponsors:
    Full-time employee of Genentech, Inc.

Helen Lin

  • Sponsors:
    Full-time employee of Genentech, Inc.

Susanne Ostrowitzki

  • Sponsors:
    Full-time employee of Genentech, Inc.

Angelica Quartino

  • Sponsors:
    Full-time employee of Genentech, Inc.

Kaycee M. Sink

  • Sponsors:
    Full-time employee of Genentech, Inc.

Jillian Smith

  • Sponsors:
    Full-time employee of F. Hoffmann-La Roche Ltd.